JP2019517541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517541A5 JP2019517541A5 JP2018563831A JP2018563831A JP2019517541A5 JP 2019517541 A5 JP2019517541 A5 JP 2019517541A5 JP 2018563831 A JP2018563831 A JP 2018563831A JP 2018563831 A JP2018563831 A JP 2018563831A JP 2019517541 A5 JP2019517541 A5 JP 2019517541A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- stabilizer
- microns
- cysteamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000003381 stabilizer Substances 0.000 claims 6
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 4
- 229960003151 mercaptamine Drugs 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 3
- 229940099500 cystamine Drugs 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- -1 hydrate Chemical class 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000013116 chronic cough Diseases 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 150000002772 monosaccharides Chemical group 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346969P | 2016-06-07 | 2016-06-07 | |
| US62/346,969 | 2016-06-07 | ||
| GBGB1609940.0A GB201609940D0 (en) | 2016-06-07 | 2016-06-07 | Microparticles |
| GB1609940.0 | 2016-06-07 | ||
| PCT/GB2017/051637 WO2017212249A1 (en) | 2016-06-07 | 2017-06-06 | Microparticles comprising a sulphur-containing compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517541A JP2019517541A (ja) | 2019-06-24 |
| JP2019517541A5 true JP2019517541A5 (enExample) | 2020-07-09 |
| JP7195934B2 JP7195934B2 (ja) | 2022-12-26 |
Family
ID=56508202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563831A Active JP7195934B2 (ja) | 2016-06-07 | 2017-06-06 | 硫黄含有化合物を含む微小粒子 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11369568B2 (enExample) |
| EP (1) | EP3463325B1 (enExample) |
| JP (1) | JP7195934B2 (enExample) |
| KR (1) | KR102412212B1 (enExample) |
| CN (1) | CN109310654A (enExample) |
| AU (1) | AU2017277897B2 (enExample) |
| BR (1) | BR112018075221B1 (enExample) |
| CA (2) | CA3026743C (enExample) |
| DK (1) | DK3463325T3 (enExample) |
| ES (1) | ES2965017T3 (enExample) |
| FI (1) | FI3463325T3 (enExample) |
| GB (1) | GB201609940D0 (enExample) |
| MX (1) | MX2018014278A (enExample) |
| SG (1) | SG11201810934TA (enExample) |
| WO (1) | WO2017212249A1 (enExample) |
| ZA (1) | ZA201807852B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| EP3572068A1 (en) * | 2018-05-22 | 2019-11-27 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | New salt of cysteamine for the preparation of highly respirable particles |
| WO2020079186A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| US12594238B2 (en) | 2020-09-03 | 2026-04-07 | Philip Morris Products S.A. | Low hygroscopicity active powder compositions |
| WO2022049488A1 (en) * | 2020-09-03 | 2022-03-10 | Philip Morris Products S.A. | Spray dried low hygroscopicity active powder compositions |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| AU2022405530A1 (en) * | 2021-12-07 | 2024-07-11 | Cila Therapeutic Inc. | Anti-viral therapeutic agents and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8901570D0 (sv) * | 1989-05-02 | 1989-05-02 | Draco Ab | Organic salts of cysteine derivatives |
| WO2006071102A1 (en) | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
| JP2012509922A (ja) * | 2008-11-27 | 2012-04-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規粉末化結晶質吸入薬 |
| EP2393491B1 (en) | 2009-02-03 | 2020-04-22 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| WO2010138419A2 (en) | 2009-05-23 | 2010-12-02 | Obio Pharmaceutical (H.K.) Ltd. | Materials and methods for treating viral infections |
| GB201021186D0 (en) * | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| JP6012716B2 (ja) | 2011-05-19 | 2016-10-25 | サヴァラ，インク． | 乾燥粉末バンコマイシン組成物および関連する方法 |
| JP5981123B2 (ja) | 2011-10-11 | 2016-08-31 | サンサ コーポレーション （バルバドス） インク | ニコチン薬の製造法およびその方法により製造される医薬 |
| AU2011379972B2 (en) * | 2011-10-26 | 2016-05-12 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| CA2864161A1 (en) * | 2012-02-10 | 2013-08-15 | Whitehead Institute For Biomedical Research | Inhibition of the glycine cleavage system for treatment of cancer |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| US9925184B2 (en) * | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
| GB201416716D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
| US10905660B2 (en) * | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
-
2016
- 2016-06-07 GB GBGB1609940.0A patent/GB201609940D0/en not_active Ceased
-
2017
- 2017-06-06 KR KR1020187035476A patent/KR102412212B1/ko active Active
- 2017-06-06 US US16/307,990 patent/US11369568B2/en active Active
- 2017-06-06 FI FIEP17735616.9T patent/FI3463325T3/fi active
- 2017-06-06 JP JP2018563831A patent/JP7195934B2/ja active Active
- 2017-06-06 CN CN201780035360.7A patent/CN109310654A/zh active Pending
- 2017-06-06 CA CA3026743A patent/CA3026743C/en active Active
- 2017-06-06 ES ES17735616T patent/ES2965017T3/es active Active
- 2017-06-06 BR BR112018075221-5A patent/BR112018075221B1/pt active IP Right Grant
- 2017-06-06 CA CA3096121A patent/CA3096121C/en active Active
- 2017-06-06 EP EP17735616.9A patent/EP3463325B1/en active Active
- 2017-06-06 AU AU2017277897A patent/AU2017277897B2/en active Active
- 2017-06-06 DK DK17735616.9T patent/DK3463325T3/da active
- 2017-06-06 SG SG11201810934TA patent/SG11201810934TA/en unknown
- 2017-06-06 WO PCT/GB2017/051637 patent/WO2017212249A1/en not_active Ceased
- 2017-06-06 MX MX2018014278A patent/MX2018014278A/es unknown
-
2018
- 2018-11-21 ZA ZA2018/07852A patent/ZA201807852B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517541A5 (enExample) | ||
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| FI3463325T3 (fi) | Mikrohiukkaset, jotka käsittävät rikkiä sisältävää yhdistettä | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| JP2015509788A5 (enExample) | ||
| JP2016534153A5 (enExample) | ||
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| JP2013536845A5 (enExample) | ||
| HRP20220919T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća | |
| JP2012176990A5 (enExample) | ||
| JP2016512494A5 (enExample) | ||
| IL273388B2 (en) | Preparations and methods for treating and improving respiratory conditions and mucosal inflammation | |
| JP2011520911A5 (enExample) | ||
| JP2012503668A5 (enExample) | ||
| JP2017528479A5 (enExample) | ||
| JP2016513625A5 (enExample) | ||
| JP2020513032A5 (enExample) | ||
| AR073528A1 (es) | Particulas inhalables que comprenden tiotropio | |
| JP2015510916A5 (enExample) | ||
| JP2022513566A5 (enExample) | ||
| JP2008518007A5 (enExample) | ||
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| JP2008502699A5 (enExample) | ||
| JP2010501520A5 (enExample) |